PDS Biotechnology Corp — Director's Dealing 2019

Mar 18, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2019-03-15

Reporting Person: Macdonald R. Loch (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-15	Common Stock	M	10000	—	Acquired	580602	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-15	Restricted Stock Units	$	M	10000	Disposed		Common Stock (10000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	7127.6	Indirect

Footnotes

F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.

F2: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.

F3: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.

F4: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.